Advertisement
Gesynta Pharma raises SEK 304 million

Gesynta Pharma has secured SEK 304 million in a Series B financing round led by Innovestor Life Science.
The funding will primarily be used for a Phase II clinical trial of vipoglanstat – a drug candidate for the treatment of endometriosis.
The financing round was led by Innovestor Life Science and included participation from existing and new investors such as Hadean Ventures, Industrifonden, Linc, Foreground Capital, Catalyze Capital, Stephen Industries and Amboy Street Ventures.
“This SEK 304 million funding round marks a pivotal milestone for Gesynta Pharma, demonstrating strong international investor confidence in our approach to treating endometriosis. With these funds, we will advance vipoglanstat towards being Phase III-ready, aiming to provide patients with a disease-modifying treatment option that overcomes the efficacy and tolerability limitations of current therapies,” says Patric Stenberg, CEO of Gesynta Pharma.
A non-hormonal drug candidate
Vipoglanstat is a novel non-hormonal drug candidate for the treatment of endometriosis. It targets mPGES-1, an enzyme upregulated in endometriotic lesions that drives both pain and lesion progression. Preclinical data have shown a marked reduction of endometriotic lesions and pain following treatment with vipoglanstat. The drug candidate has also demonstrated a favorable safety profile in previous clinical studies.
Preclinical data have shown a marked reduction of endometriotic lesions and pain following treatment with vipoglanstat.
The upcoming European Phase II trial of vipoglanstat will enroll approximately 190 patients suffering from endometriosis. The trial will evaluate the efficacy and safety profile of two dose levels of vipoglanstat against placebo over four months’ administration.

Recognizing the potential of Finnish life science innovation
Finland has become a hub for medical R&D, with many startups, established companies, and steps being taken to improve access to capital and provide business development expertise. While Finland has a long history of innovation, it was not until the early 2000s that healthcare and biotech began to attract significant venture capital (VC) investment. In […]
“The substantial medical need for improved treatments of endometriosis combined with the commercial potential of vipoglanstat presents a compelling investment opportunity, and we are delighted to support Gesynta Pharma in the development of this potentially game-changing drug candidate,” says Pekka Simula, Partner at Innovestor Life Science.
Updated: January 21, 2025, 02:15 pm
Published: January 20, 2025
Advertisement